Not provided
Not provided
Not provided
Not provided
no patient recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The heart has the ability to respond to different patho-physiological conditions by adapting its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a substrate. This is the cause of diabetic cardiomyopathy (DCM). The activation of the transcription factor PPARβ/δ allows a good use of fatty acids. The staff have demonstrated that alpha lipoic acid (AαL), a molecule with antioxidant properties present in food supplements and in certain foods (broccoli, cabbage, offal...), induces the expression of PPARβ/δ in skeletal muscle and thus increases the activity of this transcription factor.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alpha-Lipoic Acid group | Active Comparator |
| |
| placebo group | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Physiomance acide lipoïque gold | Dietary Supplement | 1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| change of LVEF between before and after 12 weeks of treatment | percentage of blood ejection before and after 12 weeks of treatment | 12 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
subjects:
Non-inclusion criteria related to MRI:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nice Hospital | Nice | 06000 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D058065 | Diabetic Cardiomyopathies |
| ID | Term |
|---|---|
| D009202 | Cardiomyopathies |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D048909 | Diabetes Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo - Physiomance acide lipoïque gold | Dietary Supplement | 1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks |
|
| D003920 |
| Diabetes Mellitus |
| D004700 | Endocrine System Diseases |